Abstract
Lung cancer is the leading cause of cancer related deaths accounting for more deaths than breast, colon and prostate cancers combined. The Rb-p16 regulatory pathway plays an essential role in tumor suppression in the lung epithelium. This is evidenced by the nearly universal alterations in Rbp16 pathway components in lung cancer, and the increased incidence of pulmonary carcinomas in persons with germline Rb mutations. Interestingly, p16 loss and Rb mutations preferentially occur in phenotypically distinct lung cancer subtypes. Analysis of human tumors has identified progressive preneoplastic lesions that accumulate molecular alterations in an orderly sequence. Epigenetic p16 gene modifications represent an early event in lung cancer progression. This review summarizes the human studies that demonstrate a critical role for the Rb-p16 tumor suppressor pathway in lung carcinogenesis, and discusses how these findings in combination with genetically engineered mouse models have significantly contributed to our understanding of lung cancer pathogenesis.
Keywords: Lung cancer, retinoblastoma, Rb, p16, cyclin D, p130
Current Molecular Medicine
Title: Retinoblastoma Regulatory Pathway in Lung Cancer
Volume: 6 Issue: 7
Author(s): Kathryn A. Wikenheiser-Brokamp
Affiliation:
Keywords: Lung cancer, retinoblastoma, Rb, p16, cyclin D, p130
Abstract: Lung cancer is the leading cause of cancer related deaths accounting for more deaths than breast, colon and prostate cancers combined. The Rb-p16 regulatory pathway plays an essential role in tumor suppression in the lung epithelium. This is evidenced by the nearly universal alterations in Rbp16 pathway components in lung cancer, and the increased incidence of pulmonary carcinomas in persons with germline Rb mutations. Interestingly, p16 loss and Rb mutations preferentially occur in phenotypically distinct lung cancer subtypes. Analysis of human tumors has identified progressive preneoplastic lesions that accumulate molecular alterations in an orderly sequence. Epigenetic p16 gene modifications represent an early event in lung cancer progression. This review summarizes the human studies that demonstrate a critical role for the Rb-p16 tumor suppressor pathway in lung carcinogenesis, and discusses how these findings in combination with genetically engineered mouse models have significantly contributed to our understanding of lung cancer pathogenesis.
Export Options
About this article
Cite this article as:
Wikenheiser-Brokamp A. Kathryn, Retinoblastoma Regulatory Pathway in Lung Cancer, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070783
DOI https://dx.doi.org/10.2174/1566524010606070783 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cyclin-Dependent Kinase-2 as a Target for Cancer Therapy: Progress in the Development of CDK2 Inhibitors as Anti-Cancer Agents
Current Medicinal Chemistry Clinical Significance of miR-1826 as a Novel Prognostic Biomarker in Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review on the Techniques for Characterizing and Predicting Human Genomic DNA Methylation
Current Bioinformatics NK-1 Receptor Antagonists: A New Generation of Anticancer Drugs
Mini-Reviews in Medicinal Chemistry The Role of Wnt/Beta-Catenin Signaling in Renal Carcinogenesis: Lessons from Cadmium Toxicity Studies
Current Molecular Medicine Micro Arrays and Biochips: Applications and Potential in Genomics and Proteomics
Current Genomics The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells
Current Cancer Drug Targets p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Silencing Human Cancer: Identification and Uses of MicroRNAs
Recent Patents on Anti-Cancer Drug Discovery Naphthoflavones as Antiproliferative Agents: Design, Synthesis and Biological Evaluation
Anti-Cancer Agents in Medicinal Chemistry Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets Studies of p53 Tumor Suppression Activity in Mouse Models
Current Genomics Complex Effect of Adenovirus Early Region Proteins on Innate Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma
Mini-Reviews in Medicinal Chemistry Advanced Glycation End Products: Association with the Pathogenesis of Diseases and the Current Therapeutic Advances
Current Clinical Pharmacology Gliomas: New Perspectives in Diagnosis, Treatment and Prognosis
Current Topics in Medicinal Chemistry Anti-Cancer Effect of Gingerol in Cancer Prevention and Treatment
Anti-Cancer Agents in Medicinal Chemistry Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition